On January 24, 2023 AnPac Bio-Medical Science Co., Ltd. (the "Company") signed definitive investment agreements with several third party investors, where the investors agreed to purchase 29,714,279 newly issued Class A ordinary shares (1,485,714 American Depositary Shares or "ADSs") of the Company at a price of US$0.175 per ordinary share or US$3.5 per ADS (1:20 ADS-to-share ratio), for a total purchase price of $5.2 million (Filing, 6-K, Anpac Bio, JAN 24, 2023, View Source [SID1234626538]). Concurrently, for each Class A ordinary share purchased, the investors will receive from the Company two warrants with each warrant to purchase one Class A ordinary share at an exercise price of $0.21 per ordinary share (2,971,428 ADS an at exercise price of $4.20 per ADS). The warrants are exercisable within 2 years from the date of issuance. The closing is expected to take place within 30 days after signing.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This Report on Form 6-K shall not constitute an offer to sell or the solicitation of an offer to buy any securities of the Company.